Navigation Links
UCB and Amgen Initiate Sclerostin Antibody Phase 3 Program in Patients With Postmenopausal Osteoporosis
Date:4/3/2012

eir nature, such forward-looking statements are not guarantees of future performance and are subject to risks, uncertainties and assumptions which could cause actual results to differ materially from those that may be implied by such forward-looking statements contained in this press release. Important factors that could result in such differences include: changes in general economic, business and competitive conditions, the inability to obtain necessary regulatory approvals or to obtain them on acceptable terms, costs associated with research and development, changes in the prospects for products in the pipeline or under development by UCB, effects of future judicial decisions or governmental investigations, product liability claims, challenges to patent protection for products or product candidates, changes in laws or regulations, exchange rate fluctuations,  changes or uncertainties in tax laws or the administration of such laws and hiring and retention of its employees.  UCB is providing this information as of the date of this press release and expressly disclaims any duty to update any information contained in this press release, either to confirm the actual results or to report a change in its expectations.

There is no guarantee that new product candidates in the pipeline will progress to product approval or that new indications for existing products will be developed and approved. Products or potential products which are the subject of partnerships, joint ventures or licensing collaborations may be subject to differences between the partners. Also, UCB or others could discover safety, side effects or manufacturing problems with its products after they are marketed.

Moreover, sales may be impacted by international and domestic trends toward managed care and health care cost containment and the reimbursement policies imposed by third-party payers as well as legislation affecting biopharmaceutical pricing and reimbursement.

Abou
'/>"/>

SOURCE Amgen
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Arthritis Foundation Announces Amgen and Wyeth to Be Presenting Sponsor of the 2008 Arthritis Walk (R)
2. Medarex to Receive Milestone Payment from Amgen
3. AMT Obtains License to Amgens GDNF Gene to Develop Treatment for Parkinsons Disease with AMTs Proprietary Gene Therapy Platform
4. Amgen, Takeda and Millennium Provide Update on Phase 3 Trial of Motesanib in Patients With Non-Small Cell Lung Cancer
5. CDC Foundation Partners with Amgen, CDC to Reduce Infections Among Cancer Patients
6. Amgen Announces Positive Top-Line Results for Denosumab in Trial for Delay of Skeletal Related Events in Bone Metastases Patients Compared to Zometa(R)
7. Amgen Issues Statement on Outcomes of Advisory Committee for Reproductive Health Drugs (ACRHD) Meeting
8. Amgen Announces Top-Line Results of Trial to Reduce Cardiovascular Events With Aranesp(R) Therapy (TREAT) in CKD Patients With Type-2 Diabetes
9. Amgen Presents Data From First Nplate(R) Study in Children With Chronic ITP
10. Amgen Highlights Data to be Presented at American Society for Bone and Mineral Research (ASBMR) Meeting
11. Amgen Board Authorizes $5 Billion Increase in Stock Repurchase Program
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... , Jan. 15, 2014 As health officials across ... virus, select Meijer pharmacies in Michigan ... to eligible patients, enabling Meijer pharmacists to administer tests and, ... set by a physician participating in the study. ...
(Date:1/15/2014)... OAKS, Calif. , Jan. 15, 2014 ... Amgen (NASDAQ: AMGN ) announced today ... jointly discover and validate new therapeutic targets and ... a chronic disorder that affects millions worldwide. The ...
(Date:1/15/2014)...  Manufacturers, suppliers and distributors of innovative medical-related products ... most important business assets, intellectual property (IP). ... Because of the highly-competitive nature of the Medical ... most litigious industry sectors of cases involving IP ...
Breaking Medicine Technology:Meijer Pharmacy Offers Free Flu, Strep Testing as Influenza Cases Rise Across the Midwest 2Meijer Pharmacy Offers Free Flu, Strep Testing as Influenza Cases Rise Across the Midwest 3Mass. General, Broad Institute and Amgen Will Work to Discover New Drugs for Inflammatory Bowel Disease 2Mass. General, Broad Institute and Amgen Will Work to Discover New Drugs for Inflammatory Bowel Disease 3Mass. General, Broad Institute and Amgen Will Work to Discover New Drugs for Inflammatory Bowel Disease 4Intellectual Property Insurance for Medical-related Products and Services 2
... Calif., Jan. 6, 2011 Genesis ... ), a biotechnology company developing targeted cancer therapies, announces that ... Biotech Showcase™ 2011 conference on Wednesday, January 12, 2011, at ... the Parc 55 Wyndham San Francisco – Union Square. ...
... Jan. 5, 2011 WebMD Health Corp. (Nasdaq: ... million of Convertible Notes due 2018 in a private placement. ... proposed offering an option to purchase up to an additional ... being offered only to qualified institutional buyers pursuant to Rule ...
Cached Medicine Technology:Genesis Biopharma to Present at 2011 Biotech Showcase Conference 2WebMD Announces Proposed Offering of Convertible Notes 2
(Date:4/17/2014)... military personnel who served in Iraq and Afghanistan ... injury (TBI) were compared to military personnel without ... Differences in measures of overall disability, cognitive function, ... are reported in an article in Journal ... Ann Liebert, Inc., publishers. The article is available ...
(Date:4/17/2014)... cause of neuronal death in Parkinson,s disease is still ... be mistaken for foreign invaders and killed by the ... diseases like type I diabetes, celiac disease, and multiple ... April 16, 2014, in Nature Communications . , ... Parkinson,s disease; but if true, it could lead to ...
(Date:4/17/2014)... of Medicine (BUSM) have discovered that the anti-seizure ... model. The findings, reported in the American ... lead to more effective treatments for alcoholism. , ... leading causes of illness and death in the ... limiting the productivity of workers and necessitating huge ...
(Date:4/17/2014)... has the potential to ward off depression among retirees, ... published online in The Journals of Gerontology, ... In the article " Internet Use and Depression Among ... Analysis ," the authors report that Internet use reduced ... among their study sample. , Late-life depression affects ...
(Date:4/17/2014)... ribbon representing a disease. A pink ribbon is well known ... think of with lung cancer?, Although white has been identified ... black may be the only one they think fits., A ... smokers between the ages of 51 to 79 years old, ... these patients, the emotional toll it can have and how ...
Breaking Medicine News(10 mins):Health News:Long-term effects of battle-related 'blast plus impact' concussive TBI in US military 2Health News:Is Parkinson's an autoimmune disease? 2Health News:BUSM researchers find anti-seizure drug may reduce alcohol consumption 2Health News:Internet use may cut retirees' depression 2Health News:Unraveling the 'black ribbon' around lung cancer 2
... of intestinal stem cells that may hold clues to the ... reported March 30 in the journal Cell , appears ... recent discovery of intestinal stem cells that multiply rapidly ... as a "brake" on cell growth and proliferation. , The ...
... renal cell carcinoma, the second most common kidney cancer subtype, ... after surgery. Those are the key findings of a multi-centre ... of the urology journal BJUI . ... to 15% of kidney cancer patients, the small number of ...
... R.I. Rhode Island Hospital physicians identified ... that required endoscopic or surgical removal. The paper calls attention ... aware of this potential danger. It is published in the ... online in advance of print. David Grand, M.D., a ...
... , WEDNESDAY, March 28 (HealthDay News) -- In ... the popular antidepressant Celexa can cause potentially fatal abnormal ... issued new dosing and use recommendations. Last August, ... than 40 milligrams a day can cause changes in ...
... radiation therapy (IMRT) instead of standard whole breast irradiation ... toxicities, according to a study in Practical Radiation ... journal of the American Society for Radiation Oncology (ASTRO)., ... effective breast cancer treatment that also reduces the incidence ...
... (HealthDay News) -- The common cold appears to increase ... makes them more sensitive, which triggers coughing, wheezing and ... are especially vulnerable to this virus-induced coughing, said the ... are known as transient receptor potential (TRP) receptors. ...
Cached Medicine News:Health News:Newly identified stem cells may hold clues to colon cancer 2Health News:Kidney cancer subtype study finds low recurrence and cancer death rates 2Health News:Rhode Island Hospital study identifies the danger of grill brushes 2Health News:FDA Adds More Warnings to Antidepressant's Label 2Health News:IMRT reduces risk of side effects in breast cancer patients 2Health News:Research Shows How Colds Lead to Coughing, Wheezing 2
Boston Multivision design is manufactured in Boston ES material for early presbyope patients. Boston Multivision lens provides crisp, clear vision at near, intermediate, and far distances and excelle...
Ophthalmic surgery stretcher. Designed for exceptional surgeon access, ideal for either superior or temporal approach....
... Reliance mobile surgical stretcher. M-701 ... of 24 in. to 32 in., ... You may specify a high range, ... A 4 in. pad can be ...
... Visionblue is a staining solution for ... required for performing a safe phaco-emulsification ... lens capsule may result in an ... risk of radial capsule tears and ...
Medicine Products: